The director of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) buys $5,625,520.00 worth of shares

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN- Get a rating) Director Gregory Bailey purchased 38,000 shares of the company in a trade dated Friday, August 19. The stock was purchased at an average price of $148.04 per share, for a total transaction of $5,625,520.00. Following the transaction, the director now owns 2,583,658 shares of the company, valued at $382,484,730.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available via this link.

Biohaven Pharmaceutical Stock Performance

Shares of BHVN traded down $0.04 in midday trading on Monday, hitting $148.01. 388,170 shares were traded, with an average volume of 1,065,997. Biohaven Pharmaceutical Holding Company Ltd. has a 52-week low of $79.01 and a 52-week high of $151.51. The stock has a fifty-day simple moving average of $145.88 and a 200-day simple moving average of $131.74. The company has a market capitalization of $10.58 billion, a P/E ratio of -9.99 and a beta of 1.03.

Analyst upgrades and downgrades

Several brokerages have recently published reports on BHVN. HC Wainwright downgraded shares of Biohaven Pharmaceutical from a “buy” rating to a “neutral” rating in a Wednesday, May 11 research report. Wedbush downgraded shares of Biohaven Pharmaceutical from an “outperform” rating to a “neutral” rating and set a price target of $148.50 for the stock. in a research report on Monday, August 8. Piper Sandler downgraded shares of Biohaven Pharmaceutical from an “overweight” rating to a “neutral” rating and set a price target of $149.00 for the stock. in a research report Thursday. SVB Leerink downgraded shares of Biohaven Pharmaceutical from an “outperform” rating to a “market perform” rating and set a price target of $150.00 for the stock. in a Wednesday, May 11 research report. Finally, Cantor Fitzgerald downgraded shares of Biohaven Pharmaceutical from an “overweight” rating to a “neutral” rating in a Wednesday, May 11 research report. Six equity research analysts gave the stock a hold rating and two gave the company a buy rating. According to data from MarketBeat.com, Biohaven Pharmaceutical has a consensus rating of “Hold” and a consensus price target of $157.17.

Institutional entries and exits

Hedge funds and other institutional investors have recently changed their holdings in the company. US Bancorp DE increased its stake in Biohaven Pharmaceutical by 19.1% in the first quarter. US Bancorp DE now owns 586 shares of the company valued at $70,000 after purchasing an additional 94 shares during the period. Montag A & Associates Inc. increased its stake in Biohaven Pharmaceutical by 16.7% in the fourth quarter. Montag A & Associates Inc. now owns 804 shares of the company valued at $111,000 after purchasing an additional 115 shares during the period. Victory Capital Management Inc. increased its stake in Biohaven Pharmaceutical by 6.4% in the first quarter. Victory Capital Management Inc. now owns 2,564 shares of the company valued at $229,000 after purchasing an additional 155 shares during the period. Washington Trust Advisors Inc. increased its holdings in Biohaven Pharmaceutical by 24.6% in the first quarter. Washington Trust Advisors Inc. now owns 810 shares of the company valued at $96,000 after purchasing an additional 160 shares during the period. Finally, Palladiem LLC increased its stake in Biohaven Pharmaceutical by 10.5% in the second quarter. Palladiem LLC now owns 1,895 shares of the company valued at $276,000 after purchasing an additional 180 shares during the period. 88.03% of the shares are currently held by hedge funds and other institutional investors.

Biohaven Pharmaceutical Company Profile

(Get a rating)

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, is developing product candidates targeting neurological and neuropsychiatric diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as the development of Rimegepant for the preventive treatment of migraine; Zavegepant which is in Phase III clinical trials for the acute and preventive treatment of migraine, as well as for respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.

Featured Articles

Insider buying and selling by quarter for Biohaven Pharmaceutical (NYSE: BHVN)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Biohaven Pharmaceutical, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Biohaven Pharmaceutical didn’t make the list.

While Biohaven Pharmaceutical currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here